Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31195044 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2ALDH1A1HTR2C | |
| SCHEMBL31195053 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2ALDH1A1HTR2C | |
| SCHEMBL31195045 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2ALDH1A1HTR2C | |
| SCHEMBL32662704 | 1.00 | SLC6A3 (0.38) | SLC6A3SLC6A4SLC6A2ALDH1A1HTR2C | |
| SCHEMBL32662737 | 0.84 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2HTR2CHTR2B | |
| SCHEMBL31335208 | 0.84 | SLC6A3 (0.39) | SLC6A3SLC6A4SLC6A2HTR2CHTR2B | |
| SCHEMBL31195028 | 0.84 | FABP7 (0.46) | SLC6A3 | |
| SCHEMBL31195004 | 0.84 | FABP7 (0.46) | SLC6A3 | |
| SCHEMBL32662349 | 0.82 | FFAR4 (0.38) | SLC6A3SLC6A4SLC6A2HTR2CHTR2B | |
| SCHEMBL31335252 | 0.82 | FFAR4 (0.38) | SLC6A3SLC6A4SLC6A2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719605-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.4) Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2026-01-15 | — | — | US | disclosed |
| WO-2024246862-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015321-A1 | CHEMICAL COMPOUNDS AND USES THEREOF | WRN, MSH2, MSH6 | SLC6A3 1334/4885SLC6A4 604/4885SLC6A2 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.